/DaVita%20Inc%20logo%20on%20building-by%20JHVEPhoto%20via%20iStock.jpg)
DaVita has outperformed other healthcare stocks over the past year, and analysts remain moderately optimistic about its growth prospects.
%20destroying%20a%20cancer%20cell%20by%20Alpha%20Tauri%203D%20Graphics%20via%20Shutterstock.jpg)
The healthcare sector has had a mixed year, yet Solventum shareholders might feel as though they drew the short straw.
Q1 Earnings Highs And Lows: DaVita (NYSE:DVA) Vs The Rest Of The Outpatient & Specialty Care Stocks
1 S&P 500 Stock Worth Investigating and 2 That Underwhelm
Kidney care leader launches its next chapter of measurable impact for patients, teammates, and communities.
1 Momentum Stock to Own for Decades and 2 We Avoid
DaVita has outpaced the broader market over the past year, with Wall Street analysts maintaining a cautiously optimistic outlook on the stock’s long-term prospects.
The 5 Most Interesting Analyst Questions From DaVita’s Q1 Earnings Call
1 Unpopular Stock That Deserves a Second Chance and 2 That Underwhelm